IPD.ASX: Quarterly Activities Report and Appendix 4C - Sep-2025 Qtr

Quarterly Activities Report and Appendix 4C - Sep-2025 Qtr

Stock	Impedimed Ltd (IPD.ASX)
Release Time	30 Oct 2025, 8:19 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

Quarterly Activities Report and Appendix 4C - Sep-2025 Qtr

Key Points

Revenue of A$3.6 million
Annual Recurring Revenue of A$14.4 million
SOZO® Core Business TCV of A$4.7 million
Cash receipts of A$3.4 million

Full Summary

ImpediMed Limited (ASX.IPD) has released its Quarterly Activities Report and Appendix 4C Cash Flow Report for the quarter ending 30 September 2025 (Q1 FY26). The company reported unaudited total revenue of A$3.6 million, a 9% increase compared to the previous quarter. Annual Recurring Revenue (ARR) increased to A$14.4 million, and the SOZO Core Business Total Contracted Value (TCV) signed during the quarter was A$4.7 million. Cash receipts from customers were A$3.4 million, with net cash outflows from operating activities of A$5.6 million. The company maintains a strong cash balance of A$23.0 million, including US$5.0 million from Tranche 2 of the US$15.0 million debt growth capital facility. Reimbursement coverage has re-accelerated, with the number of states above 80% coverage increasing to 42, and the number of states with coverage above 90% increasing to 27. The company also announced the launch of the ImpediMed Investor Hub, a new platform designed to enhance engagement and communication with its investor community.